Health Care • Biotechnology: Biological Products (No Diagnostic Substances)
$31.93 ▲ +0.20
(+0.63%)
MKT CAP: $1.77B • VOL: 417.9K
52W L $22 52W H $54
ROARABLE / RQD
D • 45/100
PIOTROSKI
2 / 9
CONSENSUS RATING DISTRIBUTION (40 DESKS)
BUY: 30 HOLD: 8
SELL: 2
12M STREET TARGET RANGE
IMPLIED: +14.0%
LOW
$27
MEDIAN
$36
MEAN
$36
HIGH
$43
STREET BS CREDIBILITY SCORE 1Y BACKTESTED
68/100
EMPIRICAL HIT RATE VS SPOT
GRADES WHETHER SELL-SIDE TARGET REVISIONS LEAD OR CHASE MAZE TAPE
MAZE // FIRM-BY-FIRM ANALYST BACKTEST & BS DETECTOR (ANR <GO>)
CURRENT 90D STREET CONSENSUS
| INSTITUTION / ANALYST | ACTION | RATING | TARGET | PRIOR PT | CALL DATE | PX AT CALL | RET SINCE CALL | 1Y ACCURACY | BS GRADE |
|---|---|---|---|---|---|---|---|---|---|
| Morgan Stanley Institutional Equity Desk | REITERATE | OUTPERFORM | $38.64 | $36.72 | 2025-02-14 | $29.06 | +9.9% | 78% | A |
| Goldman Sachs Global Research Sector Coverage | TARGET REV | STRONG BUY | $40.23 | $37.68 | 2025-02-06 | $30.01 | +6.4% | 74% | A |
| J.P. Morgan Securities US Large Cap | REITERATE | BUY | $36.40 | $35.12 | 2025-01-29 | $30.65 | +4.2% | 67% | B |
| Bernstein Autonomous Forensic Coverage | INITIATE | HOLD | $32.57 | — | 2025-01-17 | $31.29 | +2.0% | 61% | B |
| Barclays Capital Americas Research | DOWNGRADE | UNDERPERFORM | $28.10 | $30.33 | 2025-01-09 | $28.42 | -11.2% | 42% | D |
| UBS Investment Bank Institutional Desk | UPGRADE | BUY | $38.00 | $33.21 | 2024-12-18 | $27.78 | +14.9% | 72% | A |
| Citigroup Global Markets Sector Lead | TARGET REV | HOLD | $30.97 | $32.25 | 2024-12-04 | $29.69 | -4.3% | 48% | C |